{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:50:28Z","timestamp":1791546628114,"version":"4.3.4"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-022-02455-x","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T11:11:35Z","timestamp":1669201895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs"],"prefix":"10.1208","volume":"24","author":[{"given":"Sayeed","family":"Mossadeq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajen","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Bagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"2455_CR1","unstructured":"https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 - accessed December 3rd 2021"},{"key":"2455_CR2","volume":"11","author":"Russell","year":"2020","unstructured":"Russell, et al. Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection. Front Immunol. 2020;11:611337.","journal-title":"Front Immunol."},{"key":"2455_CR3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41385-020-00359-2","volume":"14","author":"Gallo","year":"2020","unstructured":"Gallo, et al. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARSCoV-2 infection. Mucosal Immunol. 2020;14:305\u201316.","journal-title":"Mucosal Immunol."},{"issue":"21","key":"2455_CR4","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"Shang","year":"2020","unstructured":"Shang, et al. Cell entry mechanisms of SARS-CoV-2. PNAS. 2020;117(21):11727\u201334.","journal-title":"PNAS."},{"key":"2455_CR5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming I, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631\u20137.","journal-title":"J Pathol"},{"key":"2455_CR6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fcimb.2020.00317","volume":"10","author":"Samavati","year":"2020","unstructured":"Samavati, et al. ACE2, Much more than just a receptor for SARS-CoV-2. Front Cell Infect Microbiol. 2020;10:317.","journal-title":"Front Cell Infect Microbiol."},{"key":"2455_CR7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/CIRCRESAHA.121.318902","volume":"128","author":"Lei","year":"2021","unstructured":"Lei, et al. SARS-CoV-2 spike protein impairs endothelial function via down regulation of ACE2. Circ Res. 2021;128:1323\u20136.","journal-title":"Circ Res."},{"key":"2455_CR8","doi-asserted-by":"crossref","first-page":"102463","DOI":"10.1016\/j.jaut.2020.102463","volume":"112","author":"G Li","year":"2020","unstructured":"Li G, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun. 2020;112:102463.","journal-title":"J Autoimmun"},{"key":"2455_CR9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","volume":"26","author":"W Sungnak","year":"2020","unstructured":"Sungnak W, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26:681\u20137.","journal-title":"Nat Med"},{"key":"2455_CR10","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106239","volume":"176","author":"Batah","year":"2021","unstructured":"Batah, et al. Pulmonary pathology of ARDS in COVID-19: a pathological review for clinicians. Respir Med. 2021;176:106239.","journal-title":"Respir Med."},{"key":"2455_CR11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395:1054\u201362.","journal-title":"The Lancet."},{"issue":"7","key":"2455_CR12","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/pharmaceutics13071077","volume":"13","author":"Eedara","year":"2021","unstructured":"Eedara, et al. Inhalation delivery for the treatment and prevention of COVID-19 infection. Pharmaceutics. 2021;13(7):1077. https:\/\/doi.org\/10.3390\/pharmaceutics13071077.","journal-title":"Pharmaceutics."},{"issue":"4","key":"2455_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/jamp.2020.1622","volume":"33","author":"Mitchell","year":"2020","unstructured":"Mitchell, et al. Urgent appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: clinicaldecision makers and governmental agencies should consider the inhaled route of administration: a statement from the ISAM Regulatory and Standardization Issues Networking Group. J Aerosol Med Pulm Drug Deliv. 2020;33(4):235\u20138. https:\/\/doi.org\/10.1089\/jamp.2020.1622.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"issue":"5","key":"2455_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"Baden et al","year":"2021","unstructured":"Baden, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England J Med. 2021;384:403-416. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","journal-title":"New England J Med."},{"key":"2455_CR15","doi-asserted-by":"publisher","unstructured":"Thomas, et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv preprint. 2021. https:\/\/doi.org\/10.1101\/2021.07.28.21261159.","DOI":"10.1101\/2021.07.28.21261159"},{"issue":"1","key":"2455_CR16","first-page":"e00341","volume":"9","author":"Wheeler","year":"2021","unstructured":"Wheeler, et al. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. Microbiology Spectrum. Am Soc Microbiol. 2021;9(1):e00341\u201321.","journal-title":"Microbiology Spectrum. Am Soc Microbiol."},{"key":"2455_CR17","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-021-24285-4","volume":"12","author":"Jalkanen","year":"2021","unstructured":"Jalkanen, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021;12:3991. https:\/\/doi.org\/10.1038\/s41467-021-24285-4.","journal-title":"Nat Commun."},{"key":"2455_CR18","doi-asserted-by":"publisher","unstructured":"Campillo-Luna J, et al. Human IgG and IgA responses to COVID-19 mRNA vaccines. medRxiv. PLOS ONE. 2021. https:\/\/doi.org\/10.1371\/journal.pone.0249499.","DOI":"10.1371\/journal.pone.0249499"},{"key":"2455_CR19","doi-asserted-by":"publisher","unstructured":"Schroeder, et al. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(202):S41-S52. https:\/\/doi.org\/10.1016\/j.jaci.2009.09.046.","DOI":"10.1016\/j.jaci.2009.09.046"},{"key":"2455_CR20","doi-asserted-by":"publisher","unstructured":"Horton, et al. Antibodies and their receptors: different potential roles in mucosal defense. Front Immunol. 2013:4. https:\/\/doi.org\/10.3389\/fimmu.2013.00200.","DOI":"10.3389\/fimmu.2013.00200"},{"key":"2455_CR21","doi-asserted-by":"crossref","unstructured":"Sterlin, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13.","DOI":"10.1126\/scitranslmed.abd2223"},{"issue":"5","key":"2455_CR22","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1006\/jmbi.1998.2556","volume":"286","author":"MK Boehm","year":"1999","unstructured":"Boehm MK, et al. The fab and fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modeling. J Mol Biol. 1999;286(5):1421\u201347.","journal-title":"J Mol Biol"},{"key":"2455_CR23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec AZ, et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. 2020;369:731\u20136.","journal-title":"Science"},{"key":"2455_CR24","doi-asserted-by":"crossref","unstructured":"Wang, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 2021;13(577):eabf1555.","DOI":"10.1126\/scitranslmed.abf1555"},{"key":"2455_CR25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cell.2022.02.005","volume":"185","author":"S Afkhami","year":"2022","unstructured":"Afkhami S, et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185:896\u2013915.","journal-title":"Cell"},{"key":"2455_CR26","unstructured":"https:\/\/www.imperial.ac.uk\/news\/203653\/landmark-coronavirus-study-trial-inhaled-imperial\/. Accessed 12 Dec\u00a02021."},{"issue":"11","key":"2455_CR27","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","volume":"26","author":"Chavda","year":"2021","unstructured":"Chavda, et al. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today. 2021;26(11):2619\u201336. https:\/\/doi.org\/10.1016\/j.drudis.2021.07.021.","journal-title":"Drug Discov Today."},{"issue":"8","key":"2455_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"Horby et al","year":"2021","unstructured":"Horby, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693-704. https:\/\/doi.org\/10.1056\/NEJMoa2021436","journal-title":"N Engl J Med."},{"issue":"7","key":"2455_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","volume":"9","author":"S Ramakrishnan","year":"2021","unstructured":"Ramakrishnan S, et al. Inhaled Budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open label, randomized controlled trial. Lancet Respir Med. 2021;9(7):763\u201372. https:\/\/doi.org\/10.1016\/S2213-2600(21)00160-0.","journal-title":"Lancet Respir Med"},{"issue":"10303","key":"2455_CR30","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","volume":"398","author":"Yu","year":"2021","unstructured":"Yu, et al. Inhaled budesonide from COVID-19 in people at high risk of complications in the community in the UK(PRINCIPLE): a randomized, controlled, open-label, adaptive platform trial. The Lancet. 2021;398(10303):843\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(21)01744-X.","journal-title":"The Lancet."},{"key":"2455_CR31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jiac.2020.04.007","volume":"26","author":"K Iwabuchi","year":"2020","unstructured":"Iwabuchi K, et al. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases. J Infect Chemother. 2020;26:625\u201332.","journal-title":"J Infect Chemother"},{"issue":"1","key":"2455_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamainternmed.2021.6759","volume":"182","author":"Clemency","year":"2022","unstructured":"Clemency, et al. Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19, a randomized clinical trial. JAMA Int Med. 2022;182(1):42\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6759.","journal-title":"JAMA Int Med."},{"key":"2455_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2009575","volume":"383","author":"Berlin","year":"2021","unstructured":"Berlin, et al. Severe Covid-19 2021. N Engl J Med. 2021;383:252021. https:\/\/doi.org\/10.1056\/NEJMcp2009575.","journal-title":"N Engl J Med."},{"issue":"1","key":"2455_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1751143721996542","volume":"1","author":"Fazzini","year":"2021","unstructured":"Fazzini, et al. Effectiveness of prone position in spontaneously breathing patients with COVID-19: a prospective cohort study. J Intensive Care Soc. 2021;1(1):1\u20134. https:\/\/doi.org\/10.1177\/1751143721996542.","journal-title":"J Intensive Care Soc."},{"key":"2455_CR35","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/jmv.26521","volume":"93","author":"J Dey","year":"2020","unstructured":"Dey J, et al. Neuroinvasion of SARS-CoV-2 may play a role in the breakdown of the respiratory center of the brain. J Med Virol. 2020;93:1296\u2013303.","journal-title":"J Med Virol"},{"issue":"5","key":"2455_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/PAS.0000000000001650","volume":"45","author":"Satturwar","year":"2021","unstructured":"Satturwar, et al. Postmortem findings associated with SARS-CoV-2., systematic review and meta analysis. Am J Surg Pathol. 2021;45(5):587\u2013603. https:\/\/doi.org\/10.1097\/PAS.0000000000001650.","journal-title":"Am J Surg Pathol."},{"key":"2455_CR37","doi-asserted-by":"publisher","unstructured":"Menter, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in the lungs and other organs suggesting vascular dysfunction. Histopathology. 2020;77 (198\u2013209)(2): https:\/\/doi.org\/10.1111\/his.14134.","DOI":"10.1111\/his.14134"},{"key":"2455_CR38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","volume":"24","author":"J Meinhardt","year":"2021","unstructured":"Meinhardt J, et al. 2021 Olfactory transmucosal SARS-CoV-2 invasion as a portal of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24:168\u201375.","journal-title":"Nat Neurosci"},{"key":"2455_CR39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s41030-019-0086-x","volume":"5","author":"G Bennett","year":"2019","unstructured":"Bennett G, et al. In vitro study of the effect of breathing pattern on aerosol delivery during high flow nasal therapy. Pulm Ther. 2019;5:43\u20135.","journal-title":"Pulm Ther"},{"key":"2455_CR40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40780-017-0076-9","volume":"3","author":"T Kondo","year":"2017","unstructured":"Kondo T, et al. Appropriate use of a dry powder inhaler based on inhalation flow pattern. J Pharm Health Care Sci. 2017;3:5.","journal-title":"J Pharm Health Care Sci"},{"issue":"3","key":"2455_CR41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/1479972316687209","volume":"14","author":"W Ramadan","year":"2017","unstructured":"Ramadan W, et al. Patterns of use of dry powder inhalers versus pressurized metered dose inhaler devices in adult patients with chronic obstructive pulmonary disease or asthma: An observational comparative study. Chronic Respir Dis. 2017;14(3):309\u201320.","journal-title":"Chronic Respir Dis"},{"key":"2455_CR42","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/thx.48.5.506","volume":"48","author":"R Melchor","year":"1993","unstructured":"Melchor R, et al. Lung deposition patterns of directly labeled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax. 1993;48:506\u201311.","journal-title":"Thorax"},{"issue":"2","key":"2455_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/jamp.2011.0891","volume":"25","author":"McCabe","year":"2021","unstructured":"McCabe, et al. ProAir HFA delivers warmer, lower impact, longer duration plumes containing higher fine particle dose than Ventolin HFA. J Aerosol Med Pulm Drug Deliv. 2021;25(2):104\u20139. https:\/\/doi.org\/10.1089\/jamp.2011.0891.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"issue":"1-2","key":"2455_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijpharm.2017.04.051","volume":"526","author":"Kunda","year":"2017","unstructured":"Kunda, et al. A novel approach study the pMDI plume using an infrared camera and to evaluate the aerodynamic properties after varying the time between actuations. Int J Pharm. 2017;526(1-2):41\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.04.051.","journal-title":"Int J Pharm."},{"issue":"23","key":"2455_CR45","doi-asserted-by":"publisher","first-page":"109","DOI":"10.14356\/kona.2005014","volume":"23","author":"P Begat","year":"2005","unstructured":"Begat P, Price R. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. KONA. 2005;23(23):109\u201321. https:\/\/doi.org\/10.14356\/kona.2005014.","journal-title":"KONA."},{"key":"2455_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120341","volume":"597","author":"Duke","year":"2021","unstructured":"Duke, et al. Increasing the fine particle fraction of pressurized metered dose inhaler solutions with novel actuator shapes. Int J Pharm. 2021;597:120341. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120341.","journal-title":"Int J Pharm."},{"key":"2455_CR47","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.rmed.2014.05.009","volume":"108","author":"P Demoly","year":"2014","unstructured":"Demoly P, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med. 2014;108:1195\u2013203.","journal-title":"Respir Med"},{"key":"2455_CR48","first-page":"131","volume":"8","author":"M Ibrahim","year":"2015","unstructured":"Ibrahim M, et al. Inhalation drug delivery devices: technology update. Med Devices: Evid Res. 2015;8:131\u20139.","journal-title":"Med Devices: Evid Res"},{"issue":"5","key":"2455_CR49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/jamp.2018.1508","volume":"32","author":"W Longest","year":"2019","unstructured":"Longest W, et al. Devices for improved delivery of the nebulized pharmaceutical aerosols to the lungs. J Aerosol Med Pulm Drug Deliv. 2019;32(5):317\u201339.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2455_CR50","unstructured":"Assessment report for COVID-19 Vaccine Moderna from European Medicines Agency. Procedure number EMEA\/H\/C\/005791\/000. 2021, EMA\/15689\/2021."},{"key":"2455_CR51","unstructured":"Background document on the mRNA-1273 vaccine (Moderna) against COVID-19. World Health Organization (WHO). 2021. WHO Reference number: WHO\/2019-nCoV\/vaccines\/SAGE-recommendation\/mRNA-1273\/background\/2021.1."},{"key":"2455_CR52","unstructured":"FDA Briefing Document titled EUA amendment request for a booster dose of the Moderna COVID-19 Vaccine. Vaccines and related biological products advisory committee meeting. 2021. https:\/\/www.fda.gov\/media\/152991\/download."},{"key":"2455_CR53","unstructured":"FDA factsheet for healthcare providers administering vaccine (vaccination providers) titled EUA of The Moderna COVID-19 vaccine to prevent COVID-19. 2021. https:\/\/eua.modernatx.com\/covid19vaccine-eua\/eua-fact-sheet-providers.pdf?."},{"key":"2455_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"Schoenmaker","year":"2021","unstructured":"Schoenmaker, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120586.","journal-title":"Int J Pharm."},{"key":"2455_CR55","unstructured":"Pfizer-BioNTech COVID-19 vaccine. FDA briefing document. Vaccines and related biological products advisory committee meeting. 2020. https:\/\/www.fda.gov\/media\/159195\/download."},{"key":"2455_CR56","doi-asserted-by":"publisher","first-page":"897190021100965","DOI":"10.1177\/08971900211009650","volume":"12","author":"Teo","year":"2021","unstructured":"Teo, et al. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. J Pharm Pract. 2021;12:8971900211009650. https:\/\/doi.org\/10.1177\/08971900211009650.","journal-title":"J Pharm Pract."},{"key":"2455_CR57","unstructured":"COMIRNATY. European Medicines Agency, Assessment report. EMA\/CHMP\/282047\/2021 Rev. 1, 22 July 2021 and Assessment report. EMEA\/H\/C\/005735\/000. EMA\/CHMP\/282047\/2021 Rev.1 Committee for Medicinal Products for Human Use (CHMP). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/comirnaty-h-c-5735-ii-0030-epar-assessmentreport-variation_en.pdf."},{"issue":"3","key":"2455_CR58","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","volume":"110","author":"Crommelin","year":"2020","unstructured":"Crommelin, et al. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2020;110(3):997\u20131001. https:\/\/doi.org\/10.1016\/j.xphs.2020.12.006.","journal-title":"J Pharm Sci."},{"issue":"1","key":"2455_CR59","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1208\/s12249-014-0210-z","volume":"16","author":"Sheth","year":"2015","unstructured":"Sheth, et al. Factors influencing aerodynamic particle size distribution of suspension pressurized metered dose inhalers. AAPS PharmsciTech. 2015;16(1):192\u2013201. https:\/\/doi.org\/10.1208\/s12249-014-0210-z.","journal-title":"AAPS PharmsciTech."},{"issue":"8","key":"2455_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10837450.2014.959176","volume":"20","author":"Zhu","year":"2014","unstructured":"Zhu, et al. Aerosol particle generation from solution-based pressurized metered dose inhalers: a technical overview of parameters that influence respiratory disease. Pharm Dev Technol. 2014;20(8):1\u201314. https:\/\/doi.org\/10.3109\/10837450.2014.959176.","journal-title":"Pharm Dev Technol."},{"issue":"7","key":"2455_CR61","doi-asserted-by":"publisher","first-page":"320A","DOI":"10.1021\/es00056a714","volume":"28","author":"Wallington","year":"1994","unstructured":"Wallington, et al. The environmental impact of CFC replacements \u2013 HFCs and HCFCs. Environ Sci Technol. 1994;28(7):320A\u20136A. https:\/\/doi.org\/10.1021\/es00056a714.","journal-title":"Environ Sci Technol"},{"key":"2455_CR62","unstructured":"United Nations Environment Program website. Available at https:\/\/www.unep.org\/news-and-stories\/story\/montreal-protocol-triumph-treaty., accessed December 16 2021"},{"key":"2455_CR63","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.2147\/DDDT.S262141","volume":"14","author":"Pritchard","year":"2020","unstructured":"Pritchard, et al. The climate is changing for metered-dose inhalers and action is needed. Drug Des Dev Ther. 2020;14:3043\u201355. https:\/\/doi.org\/10.2147\/DDDT.S262141.","journal-title":"Drug Des Dev Ther."},{"key":"2455_CR64","unstructured":"Market characterization of the U.S. metered dose inhaler industry. United States environmental protection agency., Stratospheric protection division. Office of air and radiation., Washington., D.C. 20460., September 2021. Accessible at https:\/\/www.epa.gov\/sites\/default\/files\/2021-03\/documents\/epa-hq-oar-2021-0044-0002_attachment_1-mdis.pdf"},{"issue":"1","key":"2455_CR65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/thoraxjnl-2019-213744","volume":"75","author":"Janson","year":"2019","unstructured":"Janson, et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2019;75(1):82\u20134. https:\/\/doi.org\/10.1136\/thoraxjnl-2019-213744.","journal-title":"Thorax."},{"key":"2455_CR66","doi-asserted-by":"publisher","unstructured":"Lavorini, et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011;105(7):1099\u20131103. https:\/\/doi.org\/10.1016\/j.rmed.2011.03.012.","DOI":"10.1016\/j.rmed.2011.03.012"},{"issue":"Supplement 1","key":"2455_CR67","doi-asserted-by":"crossref","first-page":"S-9","DOI":"10.1089\/jam.1995.8.Suppl_1.S-9","volume":"8","author":"G Boyd","year":"1995","unstructured":"Boyd G. The continued need for metered dose inhalers. J Aerosol Med. 1995;8(1):S-9-S\u221212.","journal-title":"J Aerosol Med"},{"issue":"2","key":"2455_CR68","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1208\/s12249-013-0063-x","volume":"15","author":"Myrdal","year":"2014","unstructured":"Myrdal, et al. Advances in metered dose inhaler technology: formulation development. AAPS Pharmsci Tech. 2014;15(2):434\u201355. https:\/\/doi.org\/10.1208\/s12249-013-0063-x.","journal-title":"AAPS Pharmsci Tech."},{"issue":"8","key":"2455_CR69","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1080\/02786826.2017.1327121","volume":"51","author":"B Gavtash","year":"2017","unstructured":"Gavtash B, et al. Transient aerodynamic atomization model to predict aerosol droplet size of pressurized metered dose inhalers (pMDI). Aerosol Sci Technol. 2017;51(8):998\u20131008.","journal-title":"Aerosol Sci Technol"},{"key":"2455_CR70","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jconrel.2011.09.089","volume":"157","author":"DS Conti","year":"2012","unstructured":"Conti DS, et al. Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation. J Control Release. 2012;157:406\u201317 (Available online 1 October 2011).","journal-title":"J Control Release"},{"issue":"7","key":"2455_CR71","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/jps.22085","volume":"99","author":"BK Bains","year":"2010","unstructured":"Bains BK, et al. In vitro reporter gene transfection via plasmid DNA delivered by metered dose inhaler. J Pharm Sci. 2010;99(7):3089\u201399.","journal-title":"J Pharm Sci"},{"key":"2455_CR72","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijpharm.2009.10.032","volume":"385","author":"Y Li","year":"2010","unstructured":"Li Y, et al. Novel pMDI formulations for pulmonary delivery of proteins. Int J Pharm. 2010;385:73\u20138.","journal-title":"Int J Pharm"},{"key":"2455_CR73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0378-5173(99)00135-0","volume":"186","author":"EA Quinn","year":"1999","unstructured":"Quinn EA, et al. Protein conformational stability in the hydrofluoroalkane propellants tetrafluoroethane and heptafluoropropane analyzed by Fourier transform Raman spectroscopy. Int J Pharm. 1999;186:31\u201341.","journal-title":"Int J Pharm"},{"key":"2455_CR74","first-page":"279","volume":"2","author":"Oliver","year":"2000","unstructured":"Oliver, et al. Initial assessment of a protein formulated in pressurized MDIs for pulmonary delivery. RDD VII. 2000;2:279\u201382.","journal-title":"RDD VII."},{"issue":"1","key":"2455_CR75","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/02786829608965351","volume":"24","author":"Brown","year":"1996","unstructured":"Brown, et al. Propellant-driven aerosols of proteins. Aerosol Sci Technol. 1996;24(1):45\u201356. https:\/\/doi.org\/10.1080\/02786829608965351.","journal-title":"Aerosol Sci Technol."},{"issue":"2","key":"2455_CR76","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0928-0987(98)00015-3","volume":"7","author":"III Williams","year":"1998","unstructured":"Williams III, et al. Formulation of a protein with propellant HFA 134a for aerosol delivery. Eur J Pharm Sci. 1998;7(2):37\u2013144. https:\/\/doi.org\/10.1016\/S0928-0987(98)00015-3.","journal-title":"Eur J Pharm Sci."},{"key":"2455_CR77","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0939-6411(03)00113-9","volume":"56","author":"T Nakate","year":"2003","unstructured":"Nakate T, et al. Comparison of the lung absorption of FK224 inhaled from a pressurized metered dose inhaler and a dry powder inhaler by healthy volunteers. Eur J Pharm Biopharm. 2003;56:319\u201325.","journal-title":"Eur J Pharm Biopharm"},{"key":"2455_CR78","first-page":"140","volume":"372","author":"BK Nyambura","year":"2009","unstructured":"Nyambura BK, et al. The processing of nanoparticles containing proteins for suspension in hydrofluoroalkane propellants. Pharm Nanotechnol. 2009;372:140\u20136.","journal-title":"Pharm Nanotechnol"},{"key":"2455_CR79","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1463-1326.2006.00647.x","volume":"8","author":"M Hausmann","year":"2006","unstructured":"Hausmann M, et al. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study., Diabetes. Obes Metab. 2006;8:574\u201380.","journal-title":"Obes Metab"},{"issue":"2","key":"2455_CR80","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1023\/a:1018997625726","volume":"9","author":"Adjei","year":"1992","unstructured":"Adjei, et al. Bioavailability of Leuprolide Acetate following nasal and inhalation delivery to rats and healthy humans. Pharm Res. 1992;9(2):244\u20139. https:\/\/doi.org\/10.1023\/a:1018997625726.","journal-title":"Pharm Res."},{"issue":"4","key":"2455_CR81","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/02652049409034255","volume":"11","author":"SP Vyas","year":"1994","unstructured":"Vyas SP, et al. Pressurized pack based liposomes for pulmonary targeting of isoprenaline \u2013 development and characterization. J Microencapsul. 1994;11(4):373\u201380.","journal-title":"J Microencapsul"},{"key":"2455_CR82","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0168-3659(87)90003-4","volume":"5","author":"SJ Farr","year":"1985","unstructured":"Farr SJ, et al. Assessing the potential of aerosol-generated liposomes from pressurized pack formulations. J Control Release. 1985;5:119\u201327.","journal-title":"J Control Release"},{"key":"2455_CR83","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1016\/j.biomaterials.2010.06.005","volume":"31","author":"B Bharatwaj","year":"2010","unstructured":"Bharatwaj B, et al. The potential for the noninvasive delivery of polymeric nanocarriers using propellant-based inhalers in the treatment of Chlamydial respiratory infections. Biomaterials. 2010;31:7376\u201385.","journal-title":"Biomaterials"},{"key":"2455_CR84","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/vaccines9091033","volume":"9","author":"N Uddin","year":"2021","unstructured":"Uddin N, et al. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines. 2021;9:1033.","journal-title":"Vaccines"},{"key":"2455_CR85","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0169-409X(90)90010-P","volume":"5","author":"PR Byron","year":"1990","unstructured":"Byron PR. Determinants of drug and polypeptide bioavailability from aerosols delivered to the lungs. Adv Drug Deliv Rev. 1990;5:107\u201332.","journal-title":"Adv Drug Deliv Rev"},{"issue":"44","key":"2455_CR86","doi-asserted-by":"crossref","first-page":"9014","DOI":"10.1021\/bi301103j","volume":"51","author":"D Lambert","year":"2012","unstructured":"Lambert D, et al. Denaturation of RNA secondary and tertiary structure by urea:simple unfolded state models and free energy parameters account for measured m-values. Biochemistry. 2012;51(44):9014\u201326.","journal-title":"Biochemistry"},{"issue":"9","key":"2455_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257018","volume":"16","author":"Malberg","year":"2021","unstructured":"Malberg, et al. Physiological respiratory parameters in pre-hospital patients with suspected COVID-19: a prospective cohort study. PLOS ONE. 2021;16(9):e0257018. https:\/\/doi.org\/10.1371\/journal.pone.0257018.","journal-title":"PLOS ONE."},{"key":"2455_CR88","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13054-021-03536-2","volume":"25","author":"G Grasselli","year":"2021","unstructured":"Grasselli G, et al. Mechanical ventilation parameters in critically ill COVID-19 patients: a scoping review. Critical Care. 2021;25:115.","journal-title":"Critical Care"},{"key":"2455_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2021.106257","volume":"208","author":"Pan","year":"2021","unstructured":"Pan, et al. Airway resistance variation correlates with prognosis of critically ill COVID-19 patients: a computational fluid dynamics study. Comp Methods Prog Biomed. 2021;208:106257. https:\/\/doi.org\/10.1016\/j.cmpb.2021.106257.","journal-title":"Comp Methods Prog Biomed."},{"issue":"3","key":"2455_CR90","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1089\/jamp.2011.0916","volume":"25","author":"C Darquenne","year":"2012","unstructured":"Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv. 2012;25(3):140\u20137. https:\/\/doi.org\/10.1089\/jamp.2011.0916.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"issue":"3","key":"2455_CR91","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1208\/s12249-014-0092-0","volume":"15","author":"Cheng","year":"2014","unstructured":"Cheng, et al. Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech. 2014;15(3):630\u201340. https:\/\/doi.org\/10.1208\/s12249-014-0092-0.","journal-title":"AAPS PharmSciTech."},{"key":"2455_CR92","first-page":"311","volume":"2","author":"Brown","year":"2002","unstructured":"Brown, et al. The stability of a particle size reduced therapeutic protein in an HFA MDI formulation. Respiratory Drug Delivery VIII. 2002;2:311\u20134.","journal-title":"Respiratory Drug Delivery VIII."},{"issue":"suppl1","key":"2455_CR93","first-page":"A91","volume":"52","author":"Kapitza","year":"2003","unstructured":"Kapitza, et al. Time action profile of a new pulmonary insulin applied with a metered-dose inhaler. Diabetes. 2003;52(suppl1):A91.","journal-title":"Diabetes."},{"issue":"1","key":"2455_CR94","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1517\/17425247.1.1.67","volume":"1","author":"Frijlink","year":"2004","unstructured":"Frijlink, et al. Dry powder inhalers for pulmonary drug delivery. Exp Opin Drug Del. 2004;1(1):67\u201386. https:\/\/doi.org\/10.1517\/17425247.1.1.67.","journal-title":"Exp Opin Drug Del."},{"key":"2455_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.02.014","volume":"314","author":"SA Shoyele","year":"2006","unstructured":"Shoyele SA, et al. Prospects of formulating proteins\/peptides as aerosols for pulmonary drug delivery. Int J Pharm. 2006;314:1\u20138.","journal-title":"Int J Pharm"},{"key":"2455_CR96","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2019.10.026","volume":"314","author":"Y Qiu","year":"2019","unstructured":"Qiu Y, et al. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J Control Release. 2019;314:102\u201315.","journal-title":"J Control Release"},{"key":"2455_CR97","doi-asserted-by":"publisher","unstructured":"Emig, et al. AUG-3387, A human-derived monoclonal antibody neutralizes SARS-CoV-2 variants and reduces viral load from therapeutic treatment of hamsters in vivo. bioRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.10.12.464150.","DOI":"10.1101\/2021.10.12.464150"},{"issue":"26","key":"2455_CR98","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1016\/j.vaccine.2011.04.029","volume":"29","author":"Audouy","year":"2011","unstructured":"Audouy, et al. Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine. 2011;29(26):4345\u201352. https:\/\/doi.org\/10.1016\/j.vaccine.2011.04.029.","journal-title":"Vaccine."},{"key":"2455_CR99","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jconrel.2013.11.013","volume":"174","author":"Patil","year":"2014","unstructured":"Patil, et al. Evaluation of a monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. J Control Release. 2014;174:51\u201362. https:\/\/doi.org\/10.1016\/j.jconrel.2013.11.013.","journal-title":"J Control Release."},{"key":"2455_CR100","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1016\/j.vaccine.2007.10.035","volume":"25","author":"J-P Amorij","year":"2007","unstructured":"Amorij J-P, et al. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB\/c mice. Vaccine. 2007;25:8707\u201317.","journal-title":"Vaccine"},{"key":"2455_CR101","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/S0264-410X(03)00224-X","volume":"21","author":"DJ Smith","year":"2003","unstructured":"Smith DJ, et al. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine. 2003;21:2805\u201312.","journal-title":"Vaccine"},{"issue":"7","key":"2455_CR102","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1073\/pnas.1017334108","volume":"108","author":"WH Lin","year":"2011","unstructured":"Lin WH, et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. PNAS. 2011;108(7):2987\u201392.","journal-title":"PNAS"},{"issue":"1","key":"2455_CR103","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/jamp.2007.0658","volume":"21","author":"JL Burger","year":"2008","unstructured":"Burger JL, et al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv. 2008;21(1):25\u201334.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2455_CR104","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1016\/j.vaccine.2014.09.071","volume":"32","author":"S Agarkhedkar","year":"2014","unstructured":"Agarkhedkar S, et al. Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled phase I clinical trials. Vaccine. 2014;32:6791\u20137.","journal-title":"Vaccine"},{"key":"2455_CR105","doi-asserted-by":"crossref","first-page":"101866","DOI":"10.1016\/j.jddst.2020.101866","volume":"59","author":"T-T Tran","year":"2020","unstructured":"Tran T-T, et al. Effects of storage on the stability and aerosolization efficiency of dry powder inhaler formulation of plasmid DNA-chitosan nanoparticles. J Drug Deliv Sci Technol. 2020;59:101866.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2455_CR106","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijpharm.2010.11.021","volume":"404","author":"WS Cheow","year":"2011","unstructured":"Cheow WS, et al. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. Int J Pharm. 2011;404:289\u2013300.","journal-title":"Int J Pharm"},{"key":"2455_CR107","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejpb.2021.08.006","volume":"168","author":"D Fiedler","year":"2021","unstructured":"Fiedler D, et al. Comparing freeze drying and spray drying of interleukins using model protein CXCL8 and its variants. Eur J Pharm Biopharm. 2021;168:152\u201365.","journal-title":"Eur J Pharm Biopharm"},{"key":"2455_CR108","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/pharmaceutics13050615","volume":"13","author":"JCK Lo","year":"2021","unstructured":"Lo JCK, et al. Inhalable protein powder prepared by spray-freeze-drying using hydroxypropyl-\u03b2-cyclodextrin as excipient. Pharmceutics. 2021;13:615.","journal-title":"Pharmceutics"},{"key":"2455_CR109","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajps.2017.10.002","volume":"13","author":"W Liang","year":"2018","unstructured":"Liang W, et al. Spray freeze drying of small nucleic acids as inhaled powder for pulmonary delivery. Asian J Pharm Sci. 2018;13:163\u201372.","journal-title":"Asian J Pharm Sci"},{"issue":"3","key":"2455_CR110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1248\/cpb.c15-00824","volume":"64","author":"H Otake","year":"2016","unstructured":"Otake H, et al. Development of spray-freeze-dried powders for inhalation with high inhalation performance and antihygroscopic property. Chem Pharm Bull. 2016;64(3):239\u201345.","journal-title":"Chem Pharm Bull"},{"issue":"3","key":"2455_CR111","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/03639045.2020.1724131","volume":"46","author":"Milani","year":"2020","unstructured":"Milani, et al. Hydroxypropyl beta cyclodextrin: a water-replacement agent or a surfactant upon spray freeze-drying of IgG with enhanced stability and aerosolization. Drug Dev Ind Pharm. 2020;46(3):403\u201311. https:\/\/doi.org\/10.1080\/03639045.2020.1724131.","journal-title":"Drug Dev Ind Pharm."},{"key":"2455_CR112","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejpb.2013.05.006","volume":"86","author":"W Liang","year":"2014","unstructured":"Liang W, et al. Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. Eur J Pharm Biopharm. 2014;86:64\u201373.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"2455_CR113","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1021\/mp500745v","volume":"12","author":"Liang","year":"2015","unstructured":"Liang, et al. Inhalable dry powder formulations of siRNA and pH responsive peptides with antiviral activity against H1N1influenza virus. Mol Pharm. 2015;12(3):910\u201321. https:\/\/doi.org\/10.1021\/mp500745v.","journal-title":"Mol Pharm."},{"issue":"1-2","key":"2455_CR114","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijpharm.2017.07.013","volume":"530","author":"Chow","year":"2017","unstructured":"Chow, et al. Inhaled powder formulations of naked siRNA using spray drying technology with L-leucine as dispersion enhancer. Int J Pharm. 2017;530(1-2):40\u201352. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.07.013.","journal-title":"Int J Pharm."},{"issue":"7","key":"2455_CR115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1248\/bpb.b13-00167","volume":"36","author":"T Okuda","year":"2013","unstructured":"Okuda T, et al. Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique. Biol Pharm Bull. 2013;36(7):183\u20131191.","journal-title":"Biol Pharm Bull"},{"issue":"12","key":"2455_CR116","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1002\/jps.10497","volume":"92","author":"Todo","year":"2003","unstructured":"Todo, et al. Improvement of insulin absorption from intratracheally administered dry powder prepared by supercritical carbon dioxide process. J Pharm Sci. 2003;92(12):2475\u201386. https:\/\/doi.org\/10.1002\/jps.10497.","journal-title":"J Pharm Sci."},{"key":"2455_CR117","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2010.12.006","volume":"150","author":"H Okamoto","year":"2011","unstructured":"Okamoto H, et al. Chitosan-interferon-\u03b2 gene complex powder for inhalation treatment of lung metastasis in mice. J Control Release. 2011;150:187\u201395.","journal-title":"J Control Release"},{"key":"2455_CR118","unstructured":"World Health Organization (WHO) Living guidelines for clinical management of COVID-19. WHO Reference number: WHO\/2019-nCoV\/clinical\/2021.2. 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2021-2."},{"issue":"1","key":"2455_CR119","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/ers.11.89","volume":"6","author":"TGD Capstick","year":"2012","unstructured":"Capstick TGD, et al. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Exp Rev Respir Med. 2012;6(1):91\u2013103.","journal-title":"Exp Rev Respir Med"},{"key":"2455_CR120","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2147\/COPD.S298514","volume":"16","author":"R Jogi","year":"2021","unstructured":"Jogi R, et al. Inspiratory flow parameters through dry powder inhalers in healthy volunteers and patients with chronic obstructive pulmonary disease (COPD): device resistance does not limit use in COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:1193\u2013201.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2455_CR121","first-page":"2247","volume":"19","author":"MA Pouya","year":"2018","unstructured":"Pouya MA, et al. Spray-freeze drying: a suitable method for aerosol delivery of antibodies in the presence of trehalose and cyclodextrins. AAPSPharmSciTech. 2018;19:2247\u201354.","journal-title":"AAPSPharmSciTech"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-022-02455-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T14:05:10Z","timestamp":1714745110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-022-02455-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["2455"],"URL":"https:\/\/doi.org\/10.1208\/s12249-022-02455-x","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"25 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"2"}}